###begin article-title 0
Analysis of SNPs and Haplotypes in Vitamin D Pathway Genes and Renal Cancer Risk
###end article-title 0
###begin p 1
Conceived and designed the experiments: PB MY SJC NR WHC PB LEM. Performed the experiments: MN DM DZ VJ HK VB VM NSD IH MY SJC. Analyzed the data: SK PR IM LEM. Contributed reagents/materials/analysis tools: PR MN DM DZ VJ HK VB VM NSD IH MY SJC IM. Wrote the paper: SK. Helped write paper: LEM.
###end p 1
###begin p 2
###xml 144 147 144 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 269 272 269 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 869 872 869 872 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 921 925 921 925 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RXRA</italic>
###xml 982 985 982 985 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 1305 1307 1305 1307 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TC</italic>
###xml 1402 1404 1402 1404 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TT</italic>
###xml 1413 1417 1413 1417 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RXRA</italic>
###xml 1765 1768 1765 1768 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 1773 1777 1773 1777 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RXRA</italic>
###xml 1283 1295 <span type="species:ncbi:9606">participants</span>
###xml 1362 1374 <span type="species:ncbi:9606">participants</span>
In the kidney vitamin D is converted to its active form. Since vitamin D exerts its activity through binding to the nuclear vitamin D receptor (VDR), most genetic studies have primarily focused on variation within this gene. Therefore, analysis of genetic variation in VDR and other vitamin D pathway genes may provide insight into the role of vitamin D in renal cell carcinoma (RCC) etiology. RCC cases (N = 777) and controls (N = 1,035) were genotyped to investigate the relationship between RCC risk and variation in eight target genes. Minimum-p-value permutation (Min-P) tests were used to identify genes associated with risk. A three single nucleotide polymorphism (SNP) sliding window was used to identify chromosomal regions with a False Discovery Rate of <10%, where subsequently, haplotype relative risks were computed in Haplostats. Min-P values showed that VDR (p-value = 0.02) and retinoid-X-receptor-alpha (RXRA) (p-value = 0.10) were associated with RCC risk. Within VDR, three haplotypes across two chromosomal regions of interest were identified. The first region, located within intron 2, contained two haplotypes that increased RCC risk by approximately 25%. The second region included a haplotype (rs2239179, rs12717991) across intron 4 that increased risk among participants with the TC (OR = 1.31, 95% CI = 1.09-1.57) haplotype compared to participants with the common haplotype, TT. Across RXRA, one haplotype located 3' of the coding sequence (rs748964, rs3118523), increased RCC risk 35% among individuals with the variant haplotype compared to those with the most common haplotype. This study comprehensively evaluated genetic variation across eight vitamin D pathway genes in relation to RCC risk. We found increased risk associated with VDR and RXRA. Replication studies are warranted to confirm these findings.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 86 87 86 87 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 88 89 88 89 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 121 124 121 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Norman1">[1]</xref>
###xml 310 313 310 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Trump1">[2]</xref>
###xml 315 318 315 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-OrdonezMoran1">[3]</xref>
###xml 378 379 378 379 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 380 381 380 381 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 409 412 409 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 513 516 513 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-OrdonezMoran1">[3]</xref>
###xml 517 520 517 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Slattery1">[6]</xref>
###xml 522 525 522 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 620 623 620 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RXR</italic>
###xml 625 628 625 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Lin1">[7]</xref>
###xml 635 642 635 642 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR-RXR</italic>
###xml 698 702 698 702 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDRE</italic>
###xml 746 747 746 747 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 748 749 748 749 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 792 795 792 795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Lin1">[7]</xref>
###xml 797 800 797 800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Holick1">[8]</xref>
Within the kidney, vitamin D is metabolized to 1,25-dihydroxycholecalciferol (1,25(OH)2D3), the active form of vitamin D [1]. The anti-carcinogenic properties of vitamin D include inhibition of clonal tumor cell proliferation, induction of immune cell differentiation and apoptosis, and decreased angiogenesis [2], [3]. Vitamin D activity is mediated through binding of 1,25(OH)2D3 to the vitamin D receptor (VDR), which can regulate transcription of other genes involved in cell regulation, growth, and immunity [3]-[6]. VDR modulates the expression of genes by forming a heterodimer complex with retinoid-X-receptors (RXR) [7]. This VDR-RXR complex is directed to the vitamin D response element (VDRE) in the promoter region of several 1,25(OH)2D3 regulated genes to initiate transcription [7], [8].
###end p 4
###begin p 5
###xml 14 15 14 15 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 16 17 16 17 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 54 57 54 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 167 170 167 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 176 179 176 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Valdivielso1">[4]</xref>
###xml 181 184 181 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Lin1">[7]</xref>
###xml 186 189 186 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Maalej1">[9]</xref>
###xml 190 194 190 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Handoko1">[11]</xref>
###xml 245 248 245 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 297 300 297 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 572 575 572 575 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 632 635 632 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 656 660 656 660 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BsmI</italic>
###xml 662 666 662 666 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FokI</italic>
###xml 668 672 668 672 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TaqI</italic>
###xml 692 696 692 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Karami1">[12]</xref>
###xml 824 825 824 825 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f</italic>
###xml 841 845 841 845 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FokI</italic>
###xml 915 917 915 917 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FF</italic>
###xml 927 931 927 931 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Karami1">[12]</xref>
###xml 980 983 980 983 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 1080 1083 1080 1083 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 1218 1221 1218 1221 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
Since 1,25(OH)2D3 exerts its activity through nuclear VDR, most studies of genetic susceptibility to vitamin D related diseases have investigated variation within the VDR gene [4], [7], [9]-[11]. However, the concert of genes that interact with VDR is vast; therefore, an analysis of variation in VDR and other genes in the vitamin D pathway may provide insight into the role of vitamin D in renal cell carcinoma (RCC) etiology. Given the importance of vitamin D metabolism in the kidney and the lack of studies that have evaluated the relationship between vitamin D, the VDR gene, and RCC, we previously evaluated how three common VDR gene polymorphisms (BsmI, FokI, TaqI) modified RCC risk [12]. We observed reduced RCC risk among older subjects and among subjects with a family history of cancer who were carriers of the f alleles in the FokI single-nucleotide polymorphism (SNP) compared with subjects with the FF genotype [12]. However, given the limited genomic coverage of VDR in our previous candidate SNP investigation, and the numerous genes that interact directly with VDR in the vitamin D pathway, we expanded upon these findings to investigate variation in candidate genes that may interact directly with VDR to modify RCC risk and improved our analysis by increasing regional coverage of variation across each gene to 80-90%.
###end p 5
###begin p 6
###xml 211 255 211 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR, RXRA, RXRB, CYP24A1, GC, STAT1, THRAP4,</italic>
###xml 260 265 260 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TRAP5</italic>
###xml 393 397 393 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-International1">[13]</xref>
Therefore, to determine whether variation in vitamin D pathway genes modified RCC risk, we comprehensively investigated the relationship between renal cancer risk and 139 tagging SNPs across eight target genes (VDR, RXRA, RXRB, CYP24A1, GC, STAT1, THRAP4, and TRAP5) of the vitamin D pathway among cases and controls from Central Europe, an area with one of the highest rates of RCC worldwide [13]. To our knowledge, this represents one of the largest and most detailed investigations of genetic variation within the vitamin D pathway and RCC risk conducted to date.
###end p 6
###begin title 7
Results
###end title 7
###begin p 8
###xml 78 85 78 85 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 1</underline>
###xml 78 85 78 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007013-t001"><underline>Table 1</underline></xref>
###xml 329 330 329 330 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 518 522 518 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Hunt1">[14]</xref>
###xml 23 35 <span type="species:ncbi:9606">participants</span>
###xml 91 103 <span type="species:ncbi:9606">participants</span>
###xml 123 135 <span type="species:ncbi:9606">participants</span>
A description of study participants and known RCC risk factors is provided in Table 1. All participants and only genotyped participants showed a similar distribution of characteristics, with the exception of sex. Cases and controls were comparable in age, but cases were more likely to have excess body mass index (BMI) (>30 kg/m2) and hypertension, and to have a first degree relative with cancer. The association with smoking was no longer observed after adjustment for age, BMI, hypertension, study center, and sex [14].
###end p 8
###begin title 9
###xml 27 39 <span type="species:ncbi:9606">participants</span>
General characteristics of participants in the CEERCC Study.
###end title 9
###begin p 10
Brno, Olomouc, Prague, Ceske-Budejovice.
###end p 10
###begin p 11
###xml 0 7 0 7 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 2</underline>
###xml 0 7 0 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007013-t002"><underline>Table 2</underline></xref>
###xml 142 145 142 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 167 183 167 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RXR-alpha (RXRA)</italic>
###xml 417 420 417 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 425 429 425 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RXRA</italic>
Table 2 lists results for global gene-based tests of association with case/control status using the minimum p-value permutation (Min-P) test. VDR (p-value = 0.02) and RXR-alpha (RXRA) (p-value = 0.10) genes were most strongly associated with RCC risk. Both the minimum p-value for all tagging SNPs within the gene and minimum false discover rate (FDR) adjusted p-values for the three SNP haplowalk sliding window for VDR and RXRA were significantly associated with RCC risk.
###end p 11
###begin title 12
Vitamin D pathway gene-based global, trend, and haplowalk minimum p-values for associations with renal cancer risk.
###end title 12
###begin p 13
Adjusted minimum p-value for all tagging SNPs in a targeted gene using additive model.
###end p 13
###begin p 14
Minimum FDR adjusted p-value for 3- SNP haplowalk sliding window analysis.
###end p 14
###begin p 15
Adjusted for age, sex, study center, and smoking status (ever, never).
###end p 15
###begin p 16
###xml 165 168 165 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 181 188 181 188 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 3</underline>
###xml 181 188 181 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007013-t003"><underline>Table 3</underline></xref>
###xml 188 189 188 189 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">)</underline>
###xml 285 293 285 293 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1</underline>
###xml 285 293 285 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007013-g001"><underline>Figure 1</underline></xref>
###xml 346 349 346 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGC</italic>
###xml 402 405 402 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAC</italic>
###xml 565 568 565 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAT</italic>
###xml 614 615 614 615 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</italic>
###xml 619 620 619 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 666 674 666 674 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1</underline>
###xml 666 674 666 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007013-g001"><underline>Figure 1</underline></xref>
###xml 755 757 755 757 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TC</italic>
###xml 879 881 879 881 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TT</italic>
###xml 951 958 951 958 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 3</underline>
###xml 951 958 951 958 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007013-t003"><underline>Table 3</underline></xref>
###xml 958 959 958 959 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">)</underline>
###xml 972 976 972 976 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RXRA</italic>
###xml 983 991 983 991 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2</underline>
###xml 983 991 983 991 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007013-g002"><underline>Figure 2</underline></xref>
###xml 991 992 991 992 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">)</underline>
###xml 1135 1137 1135 1137 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CG</italic>
###xml 1250 1252 1250 1252 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GA</italic>
###xml 515 523 <span type="species:ncbi:9606">patients</span>
###xml 733 745 <span type="species:ncbi:9606">participants</span>
###xml 829 841 <span type="species:ncbi:9606">participants</span>
Subsequently, HaploWalk based methods were used to identify regions of interest in each gene that remained significant at an FDR of less than 10%. Three significant VDR haplotypes (Table 3) were identified in two regions that were associated with increased RCC risk. The first region (Figure 1), located within intron 2, showed subjects with the AGC (OR = 1.29; 95% CI = 1.10-1.52; p-value = 0.002) or GAC (OR = 1.25; 95% CI = 1.04-1.51; p-value = 0.02) haplotype were at a significantly increased risk compared to patients with the most common referent haplotype, GAT. Increased risk appeared to be driven by the T to C change at the third loci. The second region (Figure 1), centered around intron 4, also increased RCC risk among participants with the TC (OR = 1.31; 95% CI = 1.09-1.57; p-value = 0.004) haplotype compared to participants with most common referent haplotype, TT. The R adjusted global p-values for both of these regions were 0.04 (Table 3). Across the RXRA gene (Figure 2), a single region located downstream, 3' of the coding sequence, was shown to be associated with increased RCC risk among individuals with the CG (OR = 1.35; 95% CI = 1.11-1.66; p-value = 0.003) haplotype compared to subjects with the most common haplotype, GA. The R adjusted global p-value for this region was 0.03.
###end p 16
###begin title 17
VDR HaploWalk and Haploview analysis.
###end title 17
###begin p 18
Top: HaploWalk analysis identified two chromosomal regions of interest in the vitamin D receptor (VDR) gene that were significant at an FDR of 10%. Region one included SNPs 3'- rs4760648, rs2853564, rs2254210 -5'; region two included SNPs 3'- rs12717991, rs2239179 -5'. Bottom: Haploview analysis also identified two haplotype blocks within the same chromosomal regions of interest.
###end p 18
###begin title 19
RXRA HaploWalk and Haploview analysis.
###end title 19
###begin p 20
Top: HaploWalk analysis identified a single chromosomal region of interest in the retinoid-X-receptor-alpha (RXRA) gene that was significant at an FDR of 10%. This region included SNPs 5'- rs748964, rs3118523 -3'. Bottom: Haploview analysis also identified one haplotype block within the same chromosomal region of interest.
###end p 20
###begin title 21
Renal cancer risk and haplotypes in genes in the vitamin D pathway.
###end title 21
###begin p 22
Adjusted for age (continuous), sex, study center, and smoking habit (ever, never).
###end p 22
###begin p 23
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
VDR chr12 region1: 46466932-46559981; region 2: 46545393-46544033.
###end p 23
###begin p 24
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RXRA</italic>
RXRA chr9 region1: 136475342-136473910.
###end p 24
###begin p 25
###xml 0 7 0 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s2">Results</xref>
###xml 75 83 75 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0007013.s001">Table S1</xref>
###xml 75 83 75 83 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="supplementary-material" rid="pone.0007013.s001">Table S1</xref></underline>
###xml 233 236 233 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 241 245 241 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RXRA</italic>
###xml 250 257 250 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP24A1</italic>
###xml 262 264 262 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GC</italic>
###xml 273 278 273 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STAT1</italic>
Results for individual analyses of these SNPs are provided in Supplemental Table S1. Thirteen SNPs in five vitamin D pathway genes were significantly associated with RCC risk using an additive model (number of significant tag SNPs): VDR(5), RXRA(5), CYP24A1(1), GC(1), and STAT1(1). No statistically significant interactions between these SNPs and potential confounders (i.e. BMI, age, sex, smoking status, hypertension, and a family history of cancer) were detected (data not shown). No difference in association between individual SNPs and RCC risk was observed when analyses were restricted to RCC cases histologically diagnosed with clear cell subtype (data not shown) nor when analyses were restricted to cases with only high grades tumors (data not shown).
###end p 25
###begin title 26
Discussion
###end title 26
###begin p 27
###xml 182 185 182 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 190 194 190 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RXRA</italic>
###xml 222 230 222 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a priori</italic>
###xml 322 325 322 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 454 458 454 458 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RXRA</italic>
In this analysis of 139 tagging SNPs across eight vitamin D pathway genes, we identified three regions within two genes that were significantly associated with RCC risk. Both genes, VDR and RXRA, for which we hypothesized a priori would be associated with risk, contained regions with significant associations. Across the VDR gene, three haplotypes within two regions (intron 2 and intron 4) were significantly associated with increased risk. Across the RXRA gene, RCC risk was higher among those with one particular haplotype located 3' of the coding region.
###end p 27
###begin p 28
###xml 81 84 81 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 112 116 112 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Ikuyama1">[15]</xref>
###xml 118 122 118 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Obara1">[16]</xref>
###xml 124 128 124 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Holick2">[17]</xref>
###xml 258 261 258 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 348 351 348 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 357 361 357 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Holick2">[17]</xref>
###xml 428 431 428 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 520 524 520 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Holick2">[17]</xref>
###xml 590 593 590 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 659 662 659 662 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 686 690 686 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BsmI</italic>
###xml 692 696 692 696 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FokI</italic>
###xml 698 712 698 712 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TaqI, and ApaI</italic>
###xml 749 753 749 753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Ikuyama1">[15]</xref>
###xml 755 759 755 759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Obara1">[16]</xref>
###xml 842 844 842 844 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AA</italic>
###xml 861 865 861 865 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ApaI</italic>
###xml 954 956 954 956 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AA</italic>
###xml 1076 1078 1076 1078 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Aa</italic>
###xml 1082 1084 1082 1084 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">aa</italic>
###xml 1095 1099 1095 1099 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Obara1">[16]</xref>
###xml 1182 1184 1182 1184 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TT</italic>
###xml 1201 1205 1201 1205 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TaqI</italic>
###xml 1292 1294 1292 1294 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Tt</italic>
###xml 1298 1300 1298 1300 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">tt</italic>
###xml 1328 1332 1328 1332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Ikuyama1">[15]</xref>
###xml 183 191 <span type="species:ncbi:9606">patients</span>
###xml 800 808 <span type="species:ncbi:9606">patients</span>
###xml 820 832 <span type="species:ncbi:9606">participants</span>
###xml 1160 1172 <span type="species:ncbi:9606">participants</span>
###xml 1253 1261 <span type="species:ncbi:9606">patients</span>
Only a handful of studies have comprehensively analyzed genetic variation in the VDR gene in relation to cancer [15], [16], [17]. A case-control study of 630 incident prostate cancer patients was conducted to comprehensively analyze genetic variation in the VDR gene; twenty-two SNPs were genotyped to capture a high percentage of variation in the VDR gene [17]. A two-fold increase in prostate cancer risk was observed for two VDR loci (rs2107301 and rs2238135), which were located within introns 2 and 4, respectively [17]. Though information is limited regarding the association between VDR variants and RCC risk, genetic susceptibility studies for common VDR polymorphisms, such as BsmI, FokI, TaqI, and ApaI, have been shown to modify RCC risk [15], [16]. A recent case-control study of 135 RCC patients found that participants with the AA genotype at the ApaI site had a significant increase in RCC risk (OR = 2.59; p-value = 0.01); cases with the AA genotype also were found to have lower survival rates (Relative Risk = 3.3; p-value = 0.04) compared to cases with the Aa or aa genotypes [16]. A two-fold increase in cancer risk was also reported among participants with the TT genotype at the TaqI site in a second case-control study of 102 RCC patients compared to subjects with the Tt or tt genotype (p-value = 0.001) [15].
###end p 28
###begin p 29
###xml 149 152 149 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 167 174 167 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">poly(A)</italic>
###xml 176 180 176 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TaqI</italic>
###xml 186 190 186 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BsmI</italic>
###xml 239 242 239 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 351 355 351 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Ikuyama1">[15]</xref>
###xml 357 361 357 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Ma1">[18]</xref>
###xml 363 367 363 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Fujiok1">[19]</xref>
###xml 377 380 377 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 509 513 509 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Madej1">[20]</xref>
###xml 611 614 611 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 689 690 689 690 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 772 776 772 776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Ikuyama1">[15]</xref>
###xml 778 782 778 782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Obara1">[16]</xref>
###xml 784 788 784 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Fujiok1">[19]</xref>
###xml 942 945 942 945 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RXR</italic>
###xml 967 971 967 971 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Martinet1">[21]</xref>
###xml 972 976 972 976 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Kong1">[24]</xref>
###xml 978 986 978 986 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1047 1051 1047 1051 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RXRA</italic>
###xml 1103 1104 1103 1104 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1105 1106 1105 1106 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1106 1110 1106 1110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Tokar1">[25]</xref>
###xml 1112 1116 1112 1116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Prfer1">[26]</xref>
###xml 731 739 <span type="species:ncbi:9606">patients</span>
###xml 998 1003 <span type="species:ncbi:9606">human</span>
Similarly, few previous studies of RCC risk and variation across vitamin D pathway genes have been conducted. A small number of polymorphisms in the VDR gene, such as poly(A), TaqI, and BsmI, have been speculated to result in variation of VDR expression and are hypothesized to subsequently result in changes to circulating levels of active vitamin D [15], [18], [19]. Altered VDR protein expression has been reported in a number of tumor types including breast, malignant gliomas, prostate, and colon cancer [20]. Moreover, previous epidemiological studies have reported that increased binding of vitamin D to VDR is associated with decreased RCC risk, and that active levels of vitamin D3 in serum are significantly lower in RCC patients compared to population controls [15], [16], [19]. Together these results indicate that vitamin D levels influence RCC risk. While results have been mixed concerning associations between variants in the RXR gene and cancer risk [21]-[24], in vitro animal and human studies have shown that elevated levels of RXRA increases the antiproliferative effects of 1,25(OH)2D3[25], [26].
###end p 29
###begin p 30
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 286 289 286 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-OrdonezMoran1">[3]</xref>
###xml 290 293 290 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Slattery1">[6]</xref>
###xml 460 464 460 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Ma1">[18]</xref>
###xml 791 795 791 795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Dalhoff1">[27]</xref>
###xml 1068 1072 1068 1072 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Beer1">[28]</xref>
###xml 531 537 <span type="species:ncbi:9606">humans</span>
###xml 612 620 <span type="species:ncbi:9606">patients</span>
###xml 820 828 <span type="species:ncbi:9606">patients</span>
In vitro and animal studies suggest that vitamin D and its metabolites may impede carcinogenesis by stimulating cell differentiation, inhibiting cell proliferation typically characterized by G0/G1 cell cycle arrest, apoptosis, and suppression of invassion, angiogenesis, and metastasis [3]-[6]. In laboratory studies, 1,25 hydroxyvitamin D has been shown to significantly reduce tumor growth for a variety of cancers including colon, breast, prostate and lung [18]. The use of vitamin D or its analogs as chemopreventive agents in humans, although limited, have shown beneficial effects. In a clinical trial for patients with inoperable advanced hepatocellular carcinoma a daily dose of 10 mg of Seocalcitol (a vitamin D analog) for up to one year resulted in a reduction in tumor dimension [27]. Additionally, among 37 patients with metastatic androgen-independent prostate cancer, who were treated with a high dose treatment of oral calcitriol/docetaxel (active form of vitamin D/mitotic inhibitor), prostate-specific antigen reductions of at least 50% was observed [28].
###end p 30
###begin p 31
###xml 59 62 59 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 67 71 67 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RXRA</italic>
###xml 313 316 313 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 550 553 550 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 889 893 889 893 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Sauna1">[29]</xref>
###xml 975 979 975 979 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Sauna1">[29]</xref>
###xml 981 985 981 985 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Laws1">[30]</xref>
###xml 1206 1210 1206 1210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Sauna1">[29]</xref>
###xml 1212 1216 1212 1216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Nackley1">[31]</xref>
###xml 1218 1222 1218 1222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Capon1">[32]</xref>
###xml 1454 1458 1454 1458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Nejentsev1">[33]</xref>
###xml 949 954 <span type="species:ncbi:9606">human</span>
Although the magnitude of association between RCC risk and VDR and RXRA gene variants in our study may be small, some of these variants are relatively common in the population and therefore may be associated with a much higher attributable risk as a whole compared to rare high penetrance genes. Furthermore, the VDR variants associated with RCC risk in this study were intronic and were not located near intron-exon boundaries that may produce splicing errors. These alleles seem to have no effect on the expression levels or activity of translated VDR protein and it is hypothesized that they are correlated with other variants with functional relevance. Synonymous SNPs are often disregarded in many genetic susceptibility studies based on the assumption that they do not alter amino acid sequence, which would subsequently affect protein structure and function, nor protein expression [29]. Yet, the list of synonymous mutations associated with human diseases is growing [29], [30]. Recent genetic studies have shown that synonymous mutations are not random and may play a significant role in disease etiology since synonymous SNPs can affect protein expression and function by altering mRNA stability [29], [31], [32]. Studies solely focusing on genetic variations within exonic regions of DNA that lead to changes in protein sequence may be simplistic and may not represent the larger picture that is evolving between genetic variation and disease [33].
###end p 31
###begin p 32
###xml 120 123 120 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 1341 1345 1341 1345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Wacholder1">[34]</xref>
###xml 1731 1735 1731 1735 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Core1">[35]</xref>
In addition to being one of the first genetic susceptibility studies to comprehensively examine the association between VDR and seven other vitamin D pathway genes in relation to RCC risk, an additional strength of our study includes the use of HapMap data to tag genes of interest using high (80-90%) genomic coverage by tagging genomic regions, both upstream (20 kb) and downstream (10 kb) to reduce chance of false negative findings. In this study, we also observed high participation rates, used newly diagnosed cases, included only histologically confirmed cancers, and collected biologic materials from a high proportion of subjects. The large sample size of this study provided sufficient statistical power to detect relatively small associations between genotypes and risk. Analysis of genes with significant global p-values reduced the risk of Type I errors in our study, while the use of two different Haplotype-based methods (HaploWalk and HaploStats) reduced the possibility of finding significant results based on chance. Furthermore, while hospital-based case-control studies have potential limitations due to the lack of population controls, these studies can improve response rates for the intense collection of biological specimens and therefore reduce the chances of bias in the assessment of gene-environment interactions [34]. Lastly, we did not employ a direct marker for vitamin D among these study subjects. While there is general agreement that serum 25(OH)D level is the best indicator of current vitamin D status, the biochemical marker has a short half-life and would not necessarily reflect long-term vitamin D status, particularly for case-control studies where cases have just recently been diagnosed [35].
###end p 32
###begin p 33
###xml 19 27 19 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a priori</italic>
###xml 96 99 96 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 104 108 104 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RXRA</italic>
In conclusion, our a priori hypothesis was supported and we observed that genetic variations in VDR and RXRA were significantly associated with RCC risk. However, since our results are observed within introns rather than exons and because we are only beginning to understand the role of genetic variation in intronic regions and their effect on disease development, additional studies of genetic variations of these two genes and RCC risk are warranted.
###end p 33
###begin title 34
Materials and Methods
###end title 34
###begin title 35
Study Subjects
###end title 35
###begin p 36
###xml 110 114 110 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Brennan1">[36]</xref>
###xml 681 689 <span type="species:ncbi:9606">patients</span>
###xml 754 761 <span type="species:ncbi:4097">tobacco</span>
Details of the Central and Eastern European Renal Cell Carcinoma (CEERCC) study have been previously reported [36]. Briefly, the CEERCC study is a hospital-based case-control study of renal cell cancer conducted between 1999 and 2003 in seven centers in four Central and Eastern European countries (Moscow, Russia; Bucharest, Romania; Lodz, Poland; and Prague, Olomouc, Ceske-Budejovice, and Brno, Czech Republic). Each center followed an identical protocol and was responsible for recruiting a consecutive group of newly diagnosed cases of kidney cancer as well as a comparable group of hospital controls. Controls in all centers were chosen among subjects admitted as in- or out-patients in the same hospital as the cases, with conditions unrelated to tobacco or genitourinary disorders. No single disease made up more than 20% of the control group. All subjects were residents of the study areas for at least one year at the time of recruitment and were of Caucasian descent.
###end p 36
###begin p 37
###xml 264 272 <span type="species:ncbi:9606">patients</span>
###xml 313 321 <span type="species:ncbi:9606">patients</span>
Cases between 20 and 79 years of age were ascertained through a rapid reporting system. Participating physician and other professional staff members visiting the urology, surgery, radiology, or pathology departments of participating hospitals regularly identified patients admitted for kidney cancer work-up. All patients suspected of having kidney cancer were approached for interview, but only histologically confirmed cases were included in the final analysis. All tumors were centrally reviewed to confirm diagnosis and histology. The majority of renal tumors were clear cell carcinomas (83.4%), while other subtypes included papillary (7%), chromophobe (2.4%), oncocytoma (2.3%), oncocytic neoplasms (0.2%), transitional cell carcinomas (1.1%), and unclassified (3.6%). Controls were frequency-matched to cases on age (+/-3 years), sex, and study center. A total of 1,097 confirmed incident RCC cases and 1,476 controls were included in this study. Genomic DNA was obtained from 987 of 1,097 (90%) of cases and 1,298 of 1,476 (88%) of controls. The response rates across study centers among eligible subjects who were requested to participate ranged from 90.0-98.6% for cases and 90.3-96.1% for controls.
###end p 37
###begin title 38
Interview
###end title 38
###begin p 39
###xml 64 68 64 68 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Hsu1">[37]</xref>
###xml 179 185 <span type="species:ncbi:9606">person</span>
Cases and controls were interviewed with the same questionnaire [37]. Information on demographic characteristics, medical histories, and lifestyle factors was obtained through in-person interviews by trained personnel using standardized lifestyle and food frequency questionnaires. Cases were interviewed within three months of diagnosis. Written consent for participation was obtained from all study subjects, and ethical approval was obtained for all study centers.
###end p 39
###begin title 40
Laboratory Procedures
###end title 40
###begin p 41
Genomic DNA was extracted from whole blood buffy coat using a standard phenol chloroform method. Genotyping was conducted with a GoldenGate(R) Oligo Pool All (OPA) assay by Illumina(R) () at the National Cancer Institute's (NCI's) Core Genotyping Facility (CGF) where lab staff was blinded to cases/control status. Suitable quantity and quality of genomic DNA was obtained from a subset of 777 (70.8%) RCC cases and 1,035 (70.1%) controls, due to strict quality and quantity criteria for analysis using the Illumina(R) OPA panel.
###end p 41
###begin p 42
###xml 89 132 89 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR, RXRA, RXRB, CYP24A1, GC, STAT1, THRAP4</italic>
###xml 137 143 137 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">THRAP5</italic>
###xml 381 384 381 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 502 505 502 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 510 513 510 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RXR</italic>
###xml 547 555 547 555 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a priori</italic>
###xml 614 618 614 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(GC)</italic>
###xml 722 726 722 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Verboven1">[38]</xref>
###xml 784 791 784 791 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP24A1</italic>
###xml 862 863 862 863 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 864 865 864 865 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 873 877 873 877 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Sawada1">[39]</xref>
###xml 879 883 879 883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Visnen1">[40]</xref>
###xml 949 954 949 954 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STAT1</italic>
###xml 1017 1023 1017 1023 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">THRAP4</italic>
###xml 1028 1034 1028 1034 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">THRAP5</italic>
###xml 1157 1164 1157 1164 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR-RXR</italic>
###xml 1173 1177 1173 1177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-PuzianowskaKuznicka1">[41]</xref>
###xml 1179 1183 1179 1183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Vidal1">[42]</xref>
A literature review of vitamin D associated genes helped identify eight candidate genes (VDR, RXRA, RXRB, CYP24A1, GC, STAT1, THRAP4 and THRAP5) that were ultimately selected for their involvement in vitamin D metabolism, transport, binding, function and/or expression, which may affect the mechanisms through which vitamin D may influence cancer risk. Since it is well known that VDR elicits a transcriptional response by forming a heterodimer complex with the retinoid-X-receptor, in this study both VDR and RXR were the primary genes suspected a priori to modify renal cancer risk. The group specific component (GC) vitamin D binding protein was selected for its involvement as the major carrier of vitamin D in plasma [38]. Cytochrome P450, family 24, subfamily A, polypeptide 1 (CYP24A1) was selected for its involvement in degrading and regulating 1,25(OH)2D3 levels [39], [40]. Lastly, the signal transducer and activator of transcription 1 (STAT1) and the thyroid hormone receptor associated protein 4 and 5 (THRAP4 and THRAP5) genes were selected since studies indicate that these genes may induce or suppress transcription by interacting with the VDR-RXR complex [41], [42].
###end p 42
###begin p 43
###xml 362 363 362 363 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 693 696 691 694 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 712 716 710 714 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RXRA</italic>
###xml 733 737 731 735 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RXRB</italic>
###xml 753 760 751 758 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP24A1</italic>
###xml 776 778 774 776 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GC</italic>
###xml 794 799 792 797 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STAT1</italic>
###xml 815 821 813 819 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">THRAP4</italic>
###xml 841 847 839 845 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">THRAP5</italic>
###xml 1335 1339 1333 1337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Packer1">[43]</xref>
Tag SNPs were selected to provide 80-90% genomic coverage across the genomic regions of interest. To ensure thorough coverage of the targeted region, additional coverage of regions both upstream (20 kb) of the start of transcription and downstream (10 kb) of the last exon using HapMap CEU data () among SNPs with minor allele frequencies of at least 5% and an r2>/=80% were selected. Additionally, non-synonymous SNPs or those correlated with polymorphisms with potential functional significance were included in analysis. In total, 139 SNPs in eight vitamin D-related pathway target genes were selected for analysis. The total length of sequence analyzed across all genes was 495,664 bases (VDR: 37,421 bases, RXRA: 144,022 bases, RXRB: 36,257 bases, CYP24A1: 50,537 bases, GC: 72,479 bases, STAT1: 75,061 bases, THRAP4: 39,862 bases, and THRAP5: 40,025 bases). Replicate quality control samples (5% samples) were interspersed among genotyping plates. The genotyping failure rate for the selected SNPs was 4.8% (7/146). The concordance rate between duplicate DNA samples ranged from 93-100% and completion rates ranged from 98-100%. The genotype frequencies among controls did not differ from the expected Hardy-Weinberg equilibrium proportions (p>0.05). All SNPs and assay information are reported in NCI's SNP500Cancer Database () [43].
###end p 43
###begin title 44
Statistical Analysis
###end title 44
###begin p 45
The distributions of selected characteristics and known RCC risk factors (sex, age, smoking habits, hypertension, BMI, family history of cancer, and country of residence) were compared between genotyped cases and controls using the Chi-square test. These characteristics were further evaluated to determine if associations between SNPs and RCC were modified; however, no significant interactions were observed between cancer risk, RCC risk factors, and SNPs (data not shown).
###end p 45
###begin p 46
###xml 701 702 701 702 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 762 765 762 765 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 808 809 808 809 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 832 836 832 836 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BsmI</italic>
###xml 852 856 852 856 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TaqI</italic>
###xml 860 861 860 861 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 955 959 955 959 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BsmI</italic>
The associations between individual SNPs and RCC risk were estimated by calculating odds ratios (ORs) and 95% confidence intervals (95% CI) using unconditional logistic regression. Interactions were tested comparing regression models with and without interaction terms using a likelihood ratio test (LRT). All regression models were adjusted for age (continuous), sex, study center, and smoking habit (ever, never). Additional risk factors (i.e. hypertension, BMI, and family history of cancer) were also considered, however, these variables did not affect risk estimates by at least 10%. To avoid redundant analyses, only one SNP was evaluated when high correlations were observed between two SNPs (r2>0.85). Of the 139 SNPs genotyped, two pairs of SNPs in the VDR gene were found to be highly correlated (r2 = 0.95 for rs1544410 (BsmI) and rs731236 (TaqI); r2 = 0.89 for rs2248098 and rs2239185) and therefore only one SNP was used per pair (rs1544410 (BsmI) and rs2248098).
###end p 46
###begin p 47
Since the most common form of renal cell carcinoma is of clear cell type, associations between individual SNPs and RCC risk were also evaluated among cases histologically diagnosed with this subtype of renal cancer. However restricting cases to those with clear cell type did not affect risk estimates by at least 10% (data not shown). Similarly, analyses restricted to cases with only high grades tumors did not affect risk estimates (data not shown).
###end p 47
###begin p 48
###xml 847 851 847 851 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Chen1">[44]</xref>
###xml 1036 1045 1036 1045 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0007013.s002">Figure S1</xref>
###xml 1047 1049 1047 1049 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0007013.s003">S2</xref>
###xml 1051 1053 1051 1053 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0007013.s004">S3</xref>
###xml 1055 1057 1055 1057 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0007013.s005">S4</xref>
###xml 1059 1061 1059 1061 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0007013.s006">S5</xref>
###xml 1063 1065 1063 1065 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0007013.s007">S6</xref>
###xml 1036 1065 1036 1065 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="supplementary-material" rid="pone.0007013.s002">Figure S1</xref>, <xref ref-type="supplementary-material" rid="pone.0007013.s003">S2</xref>, <xref ref-type="supplementary-material" rid="pone.0007013.s004">S3</xref>, <xref ref-type="supplementary-material" rid="pone.0007013.s005">S4</xref>, <xref ref-type="supplementary-material" rid="pone.0007013.s006">S5</xref>, <xref ref-type="supplementary-material" rid="pone.0007013.s007">S6</xref></underline>
Risk estimates were calculated for the heterozygous and homozygous variant genotypes relative to the common homozygous genotype assuming an additive model. When the frequency of the homozygous variant allele was less than 5% among controls, a dominant model was used to determine risk estimates for the presence and absence of the variant allele. Associations between SNP variants and RCC were assessed using an additive model (i.e. linear test of trend for the number of copies of the variant allele (0, 1, 2)) or a dominant model (i.e. Wald chi-square test for the presence or absence of the variant allele (0, 1)). To assess global significance of association with genes, a minimum p-value permutation (Min-P) test was used for analysis because it corrects for multiple testing while also accounting for correlations between SNPs within a gene [44]. Genes that had a significant Min-P test at a cut-off level of 10% were selected for further analysis. Analysis for genes that did not meet this criterion is available in Supplemental Figure S1, S2, S3, S4, S5, S6.
###end p 48
###begin p 49
###xml 107 108 107 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K</italic>
###xml 191 192 191 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</italic>
###xml 205 208 205 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K-1</italic>
###xml 313 317 313 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Excoffier1">[45]</xref>
###xml 395 399 395 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Chen1">[44]</xref>
###xml 742 743 742 743 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K</italic>
###xml 754 757 754 757 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K-2</italic>
###xml 913 917 913 917 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Benjamini1">[46]</xref>
HaploWalk, a haplotype-based sliding window analytic method, was used to evaluate candidate genes with N = K SNPs. The HaploWalk procedure considered a three SNP window for each SNP from SNP 2 through SNP K-1. For each window, haplotype frequencies in cases and controls were reconstructed using the EM algorithm [45], and a Wald test was used to screen for association with case-control status [44]. In the initial screening phase, no adjustment was made for potential confounders. The Wald test used a threshold value of 5%, such that haplotypes in cases and controls that had an estimated frequency below the threshold in controls were pooled into an 'other' rare haplotype category for testing. To account for multiple testing across the K SNPs, the K-2 p-values (one for each window) were adjusted for multiple comparisons using the False Discovery Rate (FDR)-controlling procedure of Benjamini and Hochberg [46]. Haplotype windows with an FDR-adjusted value of <10% were promoted to the second stage.
###end p 49
###begin p 50
###xml 132 136 132 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-R1">[47]</xref>
###xml 297 301 297 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Barrett1">[48]</xref>
###xml 398 399 398 399 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 442 446 442 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Barrett1">[48]</xref>
###xml 837 841 837 841 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Hung1">[49]</xref>
###xml 906 910 906 910 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007013-Wacholder2">[50]</xref>
In stage two, haplotype blocks identified with HaploWalk were analyzed in relation to RCC risk using Haplostats (R version 2.4.0; ) [47], adjusted for age, sex, study center, and smoking habit. Additionally, we used standard methods to identify haplotypes using the Haploview program version 3.32 [48]. Linkage disequilibrium between markers was assessed by calculating pairwise Lewontin's D' and r2 using Haploview among population controls [48]. Heterogeneity of genotype frequencies among countries was evaluated by using the likelihood ratio test to compare the fit of models with and without interaction terms, but we did not find evidence of heterogeneity across populations. No evidence of population stratification was apparent from a principal components analysis of a genome wide association study conducted in this population [49], and the likelihood of this is small among European populations [50]. Associations between common haplotypes (>5% frequency) and RCC risk were evaluated by computing ORs and 95% CIs using the most common haplotype category for comparison. All analyses were conducted in STATA 9.0 unless otherwise specified (STATA Corporation, College Station, TX).
###end p 50
###begin title 51
Supporting Information
###end title 51
###begin p 52
SNP-based analysis main effects for vitamin D pathway genes
###end p 52
###begin p 53
(1.73 MB DOC)
###end p 53
###begin p 54
Click here for additional data file.
###end p 54
###begin p 55
RXRB HaploWalk and Haploview analysis. Top: HaploWalk analysis identified no chromosomal regions of interest in the retinoid-X-receptor-beta (RXRB) gene that were significant at an FDR of 10%. The Min-P test for this gene was not statistically significant (p-value = 0.20). Bottom: Haploview analysis identified two haplotype blocks; none were associated with RCC risk when analyzed in Haplostats.
###end p 55
###begin p 56
(0.24 MB TIF)
###end p 56
###begin p 57
Click here for additional data file.
###end p 57
###begin p 58
CYP24A1 HaploWalk and Haploview analysis. Top: HaploWalk analysis identified no chromosomal regions of interest in the cytochrome P450, family 24, subfamily A, polypeptide 1 (CYP24A1) gene that were significant at an FDR of 10%. The Min-P test for this gene was not statistically significant (p-value = 0.63). Bottom: Haploview analysis identified several haplotype blocks; none were associated with RCC risk when analyzed in Haplostats.
###end p 58
###begin p 59
(0.76 MB TIF)
###end p 59
###begin p 60
Click here for additional data file.
###end p 60
###begin p 61
GC HaploWalk and Haploview analysis. Top: HaploWalk analysis identified no chromosomal regions of interest in the group specific component (GC) vitamin D binding protein that were significant at an FDR of 10%. The Min-P test for this gene was not statistically significant (p-value = 0.25). Bottom: Haploview analysis identified one haplotype block which was not associated with RCC risk when analyzed in Haplostats.
###end p 61
###begin p 62
(2.86 MB TIF)
###end p 62
###begin p 63
Click here for additional data file.
###end p 63
###begin p 64
STAT1 HaploWalk and Haploview analysis. Top: HaploWalk analysis identified a single chromosomal region of interest in the signal transducer and activator of transcription 1 (STAT1) gene that was significant at an FDR of 10%. This region included SNPs 3'- rs3755821, rs6751855, rs1467199, rs13029532 -5'. The Min-P test for this gene was not statistically significant (p-value = 0.14). Bottom: Haploview analysis also identified one haplotype block within the same chromosomal region of interest. Haplostats analysis adjusted for age, sex, study center, and smoking habit showed that subjects with the CGGA haplotype had an increased risk of RCC (OR = 1.21; 95% CI = 1.01-1.45; p-value = 0.04) compared to subjects with the referent haplotype, GACA.
###end p 64
###begin p 65
(1.76 MB TIF)
###end p 65
###begin p 66
Click here for additional data file.
###end p 66
###begin p 67
THRAP4 HaploWalk and Haploview analysis. Top: HaploWalk analysis identified no chromosomal regions of interest in the thyroid hormone receptor associated protein 4 (THRAP4) gene that were significant at an FDR of 10%. The Min-P test for this gene was not statistically significant (p-value = 0.94). Bottom: Haploview analysis identified one haplotype block which was not associated with RCC risk when analyzed in Haplostats.
###end p 67
###begin p 68
(1.42 MB TIF)
###end p 68
###begin p 69
Click here for additional data file.
###end p 69
###begin p 70
THRAP5 HaploWalk and Haploview analysis. Top: HaploWalk analysis identified no chromosomal regions of interest in the thyroid hormone receptor associated protein 5 (THRAP5) gene that were significant at an FDR of 10%. The Min-P test for this gene was not statistically significant (p-value = 0.38). Bottom: Haploview analysis identified several haplotype blocks; none were associated with RCC risk when analyzed in Haplostats.
###end p 70
###begin p 71
(0.64 MB TIF)
###end p 71
###begin p 72
Click here for additional data file.
###end p 72
###begin title 73
References
###end title 73
###begin article-title 74
Sunlight, season, skin pigmentation, vitamin D, and 25-hydroxyvitamin D: integral components of the vitamin D endocrine system.
###end article-title 74
###begin article-title 75
Anti-tumor activity of calcitriol: pre-clinical and clinical studies.
###end article-title 75
###begin article-title 76
Vitamin D and cancer: an update of in vitro and in vivo data.
###end article-title 76
###begin article-title 77
Vitamin D receptor polymorphisms and diseases.
###end article-title 77
###begin article-title 78
Newly identified actions of the vitamin D endocrine system.
###end article-title 78
###begin article-title 79
Vitamin D receptor gene (VDR) associations with cancer.
###end article-title 79
###begin article-title 80
The pleiotropic actions of vitamin D.
###end article-title 80
###begin article-title 81
Vitamin D: Its role in cancer prevention and treatment.
###end article-title 81
###begin article-title 82
Association study of VDR gene with rheumatoid arthritis in the French population.
###end article-title 82
###begin article-title 83
Association of vitamin D receptor gene polymorphism with multiple sclerosis in Japanese.
###end article-title 83
###begin article-title 84
Polymorphisms in the vitamin D receptor and their associations with risk of schizophrenia and selected anthropometric measures.
###end article-title 84
###begin article-title 85
Vitamin D receptor polymorphisms and renal cancer risk in Central and Eastern Europe.
###end article-title 85
###begin article-title 86
Renal cell carcinoma in relation to cigarette smoking: meta-analysis of 24 studies.
###end article-title 86
###begin article-title 87
Association of vitamin D receptor gene polymorphism with renal cell carcinoma in Japanese.
###end article-title 87
###begin article-title 88
Vitamin D receptor gene polymorphisms are associated with increased risk and progression of renal cell carcinoma in a Japanese population.
###end article-title 88
###begin article-title 89
Comprehensive association analysis of the vitamin D pathway genes, VDR, CYP27B1, and CYP24A1, in prostate cancer.
###end article-title 89
###begin article-title 90
Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians.
###end article-title 90
###begin article-title 91
Prevention of renal cell carcinoma by active vitamin D3.
###end article-title 91
###begin article-title 92
###xml 85 90 <span type="species:ncbi:9606">human</span>
Vitamin D receptor binding to DNA is altered without the change in its expression in human renal clear cell cancer.
###end article-title 92
###begin article-title 93
Retinoic acid receptor and retinoid X receptor alterations in lung cancer precursor lesions.
###end article-title 93
###begin article-title 94
A high-risk lesion for invasive breast cancer, ductal carcinoma in situ, exhibits frequent over expression of retinoid X receptor.
###end article-title 94
###begin article-title 95
Predictive impact of retinoid X receptor-alpha-expression in renal-cell carcinoma.
###end article-title 95
###begin article-title 96
###xml 99 104 <span type="species:ncbi:9606">human</span>
The retinoid X receptor-selective retinoid, LGD1069, down-regulates cyclooxygenase-2 expression in human breast cells through transcription factor crosstalk: implications for molecular-based chemoprevention.
###end article-title 96
###begin article-title 97
###xml 125 130 <span type="species:ncbi:9606">human</span>
Cholecalciferol (vitamin D3) inhibits growth and invasion by up-regulating nuclear receptors and 25-hydroxylase (CYP27A1) in human prostate cancer cells.
###end article-title 97
###begin article-title 98
###xml 46 49 <span type="species:ncbi:10116">rat</span>
Degradation of RXRs influences sensitivity of rat osteosarcoma cells to the antiproliferative effects of calcitriol.
###end article-title 98
###begin article-title 99
###xml 58 66 <span type="species:ncbi:9606">patients</span>
A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma.
###end article-title 99
###begin article-title 100
Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer.
###end article-title 100
###begin article-title 101
Silent Polymorphisms Speak: How They Affect Pharmacogenomics and the Treatment of Cancer.
###end article-title 101
###begin article-title 102
Expanding the association between the APOE gene and the risk of Alzheimer's disease: possible roles for APOE promoter polymorphisms and alterations in APOE transcription.
###end article-title 102
###begin article-title 103
###xml 15 16 15 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">O</italic>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure.
###end article-title 103
###begin article-title 104
A synonymous SNP of the corneodesmosin gene leads to increased mRNA stability and demonstrates association with psoriasis across diverse ethnic groups.
###end article-title 104
###begin article-title 105
Comparative high-resolution analysis of linkage disequilibrium and tag single nucleotide polymorphisms between populations in the vitamin D receptor gene.
###end article-title 105
###begin article-title 106
Joint effect of genes and environment distorted by selection biases: implications for hospital-based case-control studies.
###end article-title 106
###begin article-title 107
###xml 53 60 <span type="species:ncbi:4097">tobacco</span>
Uncommon CHEK2 mis-sense variant and reduced risk of tobacco-related cancers: case control study.
###end article-title 107
###begin article-title 108
Dietary risk factors of renal cell carcinoma in eastern and central Europe.
###end article-title 108
###begin article-title 109
###xml 58 63 <span type="species:ncbi:9606">human</span>
A structural basis for the unique binding features of the human vitamin D-binding protein.
###end article-title 109
###begin article-title 110
###xml 91 96 <span type="species:ncbi:9606">human</span>
Novel metabolism of 1 alpha,25-dihydroxyvitamin D3 with C24-C25 bond cleavage catalyzed by human CYP24A1.
###end article-title 110
###begin article-title 111
###xml 47 52 <span type="species:ncbi:9606">human</span>
Spatio-temporal activation of chromatin on the human CYP24 gene promoter in the presence of 1alpha,25-Dihydroxyvitamin D3.
###end article-title 111
###begin article-title 112
###xml 56 61 <span type="species:ncbi:9606">human</span>
Expression of thyroid hormone receptors is disturbed in human renal clear cell carcinoma.
###end article-title 112
###begin article-title 113
Stat1-vitamin D receptor interactions antagonize 1,25-dihydroxyvitamin D transcriptional activity and enhance stat1-mediated transcription.
###end article-title 113
###begin article-title 114
SNP500Cancer: a public resource for sequence validation, assay development, and frequency analysis for genetic variation in candidate genes.
###end article-title 114
###begin article-title 115
Resampling-Based Hypothesis Testing Procedures for Genetic Case-Control Association Studies.
###end article-title 115
###begin article-title 116
Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population.
###end article-title 116
###begin article-title 117
Controlling the false discovery rate: a practical and powerful approach to multiple testing.
###end article-title 117
###begin article-title 118
Haploview: analysis and visualization of LD and haplotype maps.
###end article-title 118
###begin article-title 119
International Lung Cancer Consortium: pooled analysis of sequence variants in DNA repair and cell cycle pathways.
###end article-title 119
###begin article-title 120
Counterpoint: bias from population stratification is not a major threat to the validity of conclusions from epidemiological studies of common polymorphisms and cancer.
###end article-title 120
###begin p 121
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 121
###begin p 122
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported in part by the Intramural Research Program of the US National Institutes of Health, National Cancer Institute, Division of Cancer Epidemiology and Genetics. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 122

